Seikagaku Corporation

2026/07/10 Updated
Market Cap: $242.2M (¥39.3B)
Stock Price: $4.44 (¥720)
Exchange Rate: 1 USD = ¥162.34

Stock Price Chart

2026/07/10 Updated
26.71
PER (Price Earnings Ratio)
vs Industry Avg: +17.2
0.52
PBR (Price to Book Ratio)
vs Industry Avg: -0.8
4.17%
Dividend Yield
vs Industry Avg: +1.22%

Price Trend

2026/07/10 Updated
Short-term
5-Day MA
-0.08%
Near-term
25-Day MA
-0.09%
Mid-term
75-Day MA
-2.02%
Long-term
200-Day MA
+2.79%

Price & Trading Details

2026/07/10 Updated

PRICE

Previous Close ¥719
Open ¥719
High ¥722
Low ¥719
Close ¥720

TRADING

Volume 3,400
Average Volume 136,503
Turnover ¥2,448,000
Min. Purchase ¥72,000

Earnings Calendar

Updated 2026/07/01

Recent Earnings

Date EPS Est. EPS Actual Surprise
2016/02/01 ¥40.50 ¥18.93 -53.3%
2015/02/02 ¥13.60 ¥23.85 +75.4%

Shareholder Composition

Updated 2026/07/01
42.7%
Insider Holdings
16.4%
Institutional
40.9%
Public Float
41
Institutional Holders
Insider Holdings 42.7%
Institutional 16.4%
Public Float 40.9%

Major Holders

Updated 2026/07/01
Institution Ownership Shares Change
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
0.90%
510.5K 0.00%
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
0.62%
350.4K 0.00%
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
0.32%
181.1K +68.31%
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
0.20%
115.8K -10.64%
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
0.18%
101.8K -18.69%
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
0.15%
83.1K -43.78%

Dividend History

Updated 2026/07/05
-%
Dividend Yield
¥15
Annual Dividend
-50.0%
YoY Growth
55.6%
Payout Ratio
Year Dividend Change
2026 ¥15 -50.0%
2025 ¥30 +7.1%
2024 ¥28 +7.7%
2023 ¥26 -7.1%
2022 ¥28 -

Financial Performance

2026/07/05 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2023 2024 2025 2026
Income Statement
Revenue ¥33,456M ¥36,213M ¥39,374M ¥36,645M
Gross Profit ¥18,024M ¥16,877M ¥19,153M ¥15,972M
Operating Income ¥2,116M ¥434M ¥1,336M -¥658M
Pretax Income ¥3,074M ¥1,695M ¥1,937M ¥1,519M
Net Income ¥2,236M ¥2,186M ¥1,214M ¥1,473M
EPS ¥40.49 ¥40.08 ¥22.25 ¥26.99
Operating Margin 6.32% 1.20% 3.39% -1.80%
Balance Sheet
Total Assets ¥75,625M ¥81,795M ¥83,872M ¥86,344M
Total Equity ¥67,216M ¥72,281M ¥73,185M ¥75,298M
Total Liabilities ¥8,409M ¥9,514M ¥10,687M ¥11,046M
Cash ¥23,451M ¥15,439M ¥15,132M ¥8,938M
Interest-bearing Debt ¥389M ¥396M ¥380M ¥356M
Equity Ratio 88.88% 88.37% 87.26% 87.21%
D/E Ratio 0.01 0.01 0.01 0.00
Cash Flow
Operating CF ¥1,574M ¥513M ¥4,429M -¥1,347M
Investing CF ¥3,365M -¥7,209M -¥3,540M -¥3,508M
Financing CF -¥3,244M -¥1,461M -¥1,571M -¥1,677M
Free CF -¥478M -¥4,047M -¥179M -¥7,371M
Efficiency
ROE 3.33% 3.02% 1.66% 1.96%
ROA 2.96% 2.67% 1.45% 1.71%

Company Information

English Name Seikagaku Corporation
Japanese Name 生化学工業(株)
Stock Code 4548.T (JPX)
Sector / Industry Healthcare / Medical Devices
Employees 1,142

About

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. It also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, the company develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate used in artificial dialysis. Further, its products under development include SI-6603 for lumbar disc herniation; SI-614, a dry eye treatment; SI-613 for osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was incorporated in 1947 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance